Nonagen Bioscience is pioneering advanced diagnostic technologies aimed at improving the management of bladder cancer through its flagship product, Oncuria®. This innovative multiplex protein immunoassay is designed to quantitatively detect a specific set of ten biomarkers in urine, which are closely associated with bladder cancer. The Oncuria test not only aids in the diagnosis of bladder cancer but also plays a crucial role in monitoring patients with early-stage disease for recurrence and predicting their response to bacillus Calmette-Guérin (BCG) therapy. With demonstrated sensitivity and specificity rates of 93%, Oncuria offers a reliable alternative to traditional urine-based diagnostic methods, particularly for detecting low-grade tumors, which are often challenging to identify.

The technology behind Oncuria leverages noninvasive liquid biopsies, utilizing a proprietary set of cancer biomarkers that have been validated through extensive research collaborations. The diagnostic process involves a sophisticated multivariate classifier algorithm that analyzes protein expression patterns and clinical data, producing a customized report that indicates the likelihood of bladder cancer presence. This rapid analysis, facilitated by a HIPAA-compliant cloud-based system, empowers healthcare providers to make informed decisions regarding patient care and counseling. Nonagen Bioscience's commitment to advancing bladder cancer diagnostics is further underscored by the Breakthrough Device Designation received from the FDA, highlighting the potential clinical benefits of Oncuria in transforming bladder cancer management.

United States

Nonagen Bioscience is a biotechnology company that specializes in developing first-in-class diagnostics for early detection and prediction of human cancers.

Nonagen Bioscience

Company Details